Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Colon cancer
Stage/Subtype:  stage III colon cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 55 for your search:
Start Over
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.52, NCI-2014-02486, 2012-000095-42, NCT02149108
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Biological Therapy in Improving Immune Reconstitution after Chemotherapy in Older Patients with Stage I-III Breast, Stage II Bladder, or Stage II-III Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 11-C-0146, NCI-2013-01487, 110146, P09590, NCT01339000
Exercise and Metformin Hydrochloride in Lowering Insulin Levels in Colorectal or Breast Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training, Treatment
Age: 18 and over
Trial IDs: 11-009, NCI-2011-02702, NCT01340300
Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Relapsed or Refractory Colorectal Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1214, NCI-2012-01337, CIR00009096, NA_00069666, NA_00069666 / CIR00009096, NCI-2013-01567, NCT01639131
Ziv-Aflibercept and Combination Chemotherapy in Treating Patients with Previously Untreated Colorectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 11182, NCI-2012-01167, 2012C0055, NCT01652196
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116833, NCI-2014-00142, NCT01750918
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-224, NCI-2014-01095, NCT01776307
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NA_00085756 / CIR00007001, NCT01876511
Neuromodulation with Interstim Device in Reducing Bowel Dysfunction after Surgery in Patients with Rectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-100, NCI-2014-01368, NCT02163187
Anti-B7H1 Monoclonal Antibody MEDI4736 in Treating Patients with Locally Advanced or Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-109, NCI-2014-02513, NCT02227667
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13050, NCI-2015-01790, NCT02425683
Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin C Followed by Standard Chemotherapy in Treating Patients With Peritoneal Carcinomatosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-09-332, NCI-2013-01214, 11-075, NCT02040142
Start Over